Jefferies gives PPDI buy rating

Pharmaceutical Product Development, Inc. was rated at buy by Jefferies & Co., Inc. analyst David Windley. Jefferies increased its price target to $42 from $36.50. The company reported first-quarter operating results of $0.36, beating consensus by one cent. Sales of $276.7 million exceeded the analyst's estimate of $274 million and consensus of $275 million. Shares of the Wilmington, N.C., pharmaceutical company were up 20 cents, or 0.53%, at $37.75 on volume of 1,064,568 shares versus the three-month running average of 752,730 shares. (Nasdaq: PPDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.